Last reviewed · How we verify
CKD-387
At a glance
| Generic name | CKD-387 |
|---|---|
| Also known as | Test |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting Conditions (PHASE1)
- Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting Condition (PHASE1)
- Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed Conditions (PHASE1)
- Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1 (PHASE1)
- The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375 (PHASE1)
- Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy Adults (PHASE1)
- The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed Condition (PHASE1)
- Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-387 CI brief — competitive landscape report
- CKD-387 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI